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Materials and Methods  
Materials: Chemicals were of reagent grade quality or better, obtained from commercial 
suppliers and used without further purification. Vitamin B12 was a generous gift from DSM 
Nutritional products AG (Basel/Switzerland) and Prof. B. Jaun (retired ETH Zurich). All 
solvents were of reagent, analytical, HPLC or LC-MS grade respectively and obtained from 
commercial suppliers. Bidistilled water was used in all reactions.  
 
Analytical HPLC: Spectra were recorded on an Acquity Waters system equipped with a 
PDA detector and an autosampler using a Nucleosil C18 250/3 column from Macherey-Nagel. 
A gradient (0-5 min 25% A; 5-30 min 25-100% A) of methanol (solvent A) versus bidistilled 
water containing 0.1% trifluoroacetic acid (solvent B) was applied using a flow rate of 0.3 
mL/min. 
 
Preparative HPLC: Separations were conducted on a VWR LaPrep system equipped with a 
PDA detector and a Nucleosil C18 250/40 column from Macherey-Nagel. A gradient (0-3 min 
5% C; 3-3.20 min 25% C; 3.20-30 min 25-33% C) of acetonitrile (solvent C) versus 
bidistilled water containing 0.1% trifluoroacetic acid (solvent B) was applied using a flow rate 
of 40 mL/min. 
 
ESI-MS: Spectra were recorded on a Bruker Daltonics HTC ESI-MS operated in the positive 
or negative mode. Injection rate 3 PL/min. Nebulizer P =10 psi, dry gas flow rate 5 L/min, gas 
T = 350 ºC. All solvents used were of LCMS grade. 
 
ICP/OES: Inductively coupled plasma/optical emission spectrometry (ICP/OES) 
measurements were performed on a Perkin Elmer Optima 7300 V HF ICP-OES Spectrometer. 
 
HR-ESI-MS: Spectra were recorded on a Bruker maXis QTOF-MS instrument (Bruker 
Daltonics GmbH, Bremen, Germany). The samples were dissolved in MeOH and analyzed via 
continuous flow injection at 3 μL/min. The mass spectrometer was operated in positive ion 
mode with a capillary voltage of 4 kV, an endplate offset of –500 V, nebulizer pressure of 5.8 
psig, and a drying gas flow rate of 4 L/min at 180°C. The instrument was calibrated with a 
sodium formate solution (500μl H2O: 500μl iPrOH: 20μl HCOOH: 20μl 0.1 M NaOHaq). The 
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resolution was optimized at 30’000 FWHM in the active focus mode. The accuracy was better 
than 2 ppm in a mass range between m/z 118 and 1600. 
 
Spectroscopy: UV-Vis spectra were recorded on a Varian Cary 50 using quartz cells with a 
path length of 1 cm. Citation of λmax (log ε) in nm. For platelet studies, spectra were recorded 
on a Perkin Elmer double beam spectrophotometer Lambda 950 using quartz cells with a 1 cm 
path length. The kinetics of carbon monoxide release from CO donor compounds were 
studied by recording spectra at the Soret band region (Omax = 424 nm) and observing the 
conversion from deoxyMb to MbCO at room temperature. Solutions of Mb (Myoglobin from 
equine heart, SIGMA) were prepared fresh by dissolving the protein in deionized water in 
such amount to obtain final concentrations 10 or 100 μM. Sodium dithionite (1 mg/ml, eq. 
0.1%) was added just before measurements to convert myoglobin to deoxyMb. Before every 
experiment the reference spectra of deoxygenated protein were recorded. Solutions of CO 
donor compounds dissolved in DMSO:PBS (50:50) were added to the quartz cuvettes with 
deoxyMb in such amounts to give final concentrations of 10 or 100 μM. All solutions were 
always overlaid with mineral oil (0.5 cm3) to prevent CO escaping and myoglobin being 
oxygenated. 1H- and 13C-NMR as well as 2D-NMR spectra were recorded on a 500 MHz 
Oxford NMR AS 500 using a QNP probe head and MestReNova 6.0.2 as evaluation tool. All 
spectra were recorded in D2O at 300 K and TSP was used as a reference for all 13C-NMR 
experiments. 
 
Cyclic voltammetry: Cyclic voltammograms were obtained on a Metrohm 757 VA 
Computrace System. Measurements were performed using a glassy carbon electrode (working 
electrode) and an Ag/AgCl electrode (reference electrode). Samples were dissolved in 2 mL 
of 0.1 M TRIS buffered at pH 8. Hexacyanoferrate (0.5 mM) was used as an internal 
reference. Samples were purged with N2 (g) for 5 minutes prior to each measurement. The 
measurement was accepted if EK3[Fe(CN)6] was found between +179 and +186 mV.  
Solid Phase Extraction: Chromafix C18ec columns were applied for solid phase extraction 
(SPE). The compounds were dissolved in water, transferred to the adsorbent, washed with 
water and eluted with MeOH. 
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Experimental procedures 
Cyanocobalamin-c-lactone (2). The synthesis was performed according to a procedure 
reported by Bonnet et al.S1 Vitamin B12 (100 mg 74 Pmol, 1 equiv) was dissolved in 1 M HCl 
(10 mL) and H2O (100 mL). Chloramin-T (25.2 mg, 110 Pmol 1.5 equiv) was dissolved in 
H2O (50 mL) and was added drop wise over a period of 60 minutes. The pink solution was 
desalted over Amberlite XAD-2. Purification by preparative HPLC and lyophilization 
afforded 2 in good yields (82 mg, 60.6 Pmol, 82%) UV-Vis (c = 1.66.10-5 M) O/nm (log ε) = 
278 (4.0), 289 (3.9), 306 (4.1), 359 (4.5), 409 (3.4), 523 (3.7), 551 (3.7). HPLC tR = 14.9 min. 
ESI-MS (H2O:MeOH 1:1) m/z = 677.9 [100%; M+2H]2+, 1354.5 [95%; M+H]+ (m/zcalc for 
C63H86BrCoN13O15P: 1354.5). CV (0.1 M TRIS pH 8, K3[Fe(CN)6]) Ered  = -929 mV. 1H 
NMR (D2O; 500 MHz; 300K) G/ppm  =  7.32 (s, 1H), 7.12 (s, 1H), 6.44 (s, 1H), 6.37 (d, J = 
3.2 Hz, 1H), 6.09 (s, 1H), 4.29 (m, 2H), 4.20 (dd, J = 8.9, 1.9 Hz, 1H), 4.09 (m, 2H), 3.93 (dd, 
J = 12.9, 2.4 Hz, 1H), 3.75 (dd, J = 12.9, 4.0 Hz, 1H), 3.61 (d, J = 14.4 Hz, 1H), 3.38 (d, J = 
9.8 Hz, 1H), 3.30 – 3.26 (m, 1H), 2.99 – 2.92 (m, 2H), 2.85-1.15 (m, 35H), 2.61 (s, 3H), 2.57 
(s, 3H), 2.29 (s, 3H), 2.27 (s, 3H), 1.93 (s, 3H), 1.49 (s, 3H), 1.42 (s, 3H), 1.38 (s, 3H), 1.26 
(d, J = 6.3 Hz, 3H), 1.17 (s, 3H), 0.50 (s, 3H). 
 
10-bromo-cyanocobalamin (3). The synthesis was performed by a modified procedure of 
Wagner.S2 Vitamin B12 (100 mg, 74 μmol, 1 equiv) was dissolved in glacial AcOH (3 ml) and 
NBS (13 mg, 74 μmol, 1 equiv) was added in small portions (~0.5 mg) over a period of 3 h. 
The resulting dark purple solution was desalted with solid phase extraction (SPE) and the 
solvents were removed under reduced pressure. Purification by preparative HPLC and 
lyophilization afforded 3 in quantitative yields (105 mg, 73 μmol, 99 %) as a purple powder. 
UV-vis (c = 6.05.10-5 M; H2O) O/nm (log ε) = 283 (3.9), 289 (3.9), 365 (4.3), 415 (3.3), 550 
(3.7), 576 (3.7). HPLC tR = 16.5 min. ESI-MS (H2O:MeOH 1:1) m/z = 718.2 [100%; 
M+2H]2+, 1435.5 [70%; M+H]+ (m/zcalc for C63H88BrCoN14O14P: 1435.48); HR-ESI-MS 
(MeOH, NaI) m/z = 740.2279 [100%; M+2Na]2+ (m/zcalc for C63H87BrCoN14O14PNa2: 
740.2281). CV (0.1 M TRIS pH 8, K3[Fe(CN)6]) Ered  = -798 mV. 1H NMR (500 MHz, D2O) 
δ/ppm =  7.31 (s, 1H), 7.13 (s, 1H), 6.52 (s, 1H), 6.37 (d, J = 3.1 Hz, 1H), 4.43 – 4.39 (m, 
1H), 4.33 – 4.31 (m, 2H), 4.25 (d, J = 8.4 Hz, 1H), 4.07 (t, J = 8.6 Hz, 3H), 3.96 – 3.92 (m, 
1H), 3.78 (dd, J = 12.9, 3.8 Hz, 2H), 3.69 – 3.56 (m, 3H), 3.40 (d, J = 8.8 Hz, 1H), 2.99 (dd, J 
= 14.4, 9.3 Hz, 1H), 2.80-1.10 ppm (m, 36H), 2.61 (s, 3H), 2.58 (s, 3H), 2.29 (s, 3H), 2.28 (s, 
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3H), 1.93 (s, 3H), 1.83 (s, 3H), 1.41 (s, 3H), 1.39 (s, 3H), 1.34 (s, 3H), 1.28 (d, J = 6.2 Hz, 
3H), 0.39 (s, 3H). 
 
10-chloro-cyanocobalamin (4). To vitamin B12 (100 mg, 74 μmol, 1 equiv) dissolved in 
glacial AcOH (3 ml) NCS (10 mg, 73 μmol, 1.0 equiv) was added over a period of 3 h. The 
resulting dark purple solution was desalted with solid phase extraction (SPE) and the solvents 
were removed under vacuum. Purification by preparative HPLC and lyophilization afforded 4 
(75 mg, 55 μmol, 75%) as a purple powder. UV-vis (c = 4.75.10-5M; H2O) O/nm (log ε) = 282 
(3.9), 289 (3.9), 364 (4.2), 408 (3.3), 551 (3.6), 574 (3.7); HPLC tR = 16.0 min; ESI-MS 
(H2O:MeOH 1:1) m/z = 695.3 [100%; M+2H]2+, 1389.5 [70%; M+H]+ (m/zcalc for 
C63H88ClCoN14O14P: 1389.53); HR-ESI-MS (MeOH, NaI) m/z = 717.2531 [100%; 
M+2Na]2+ (m/zcalc for C63H87ClCoN14O14PNa2: 717.2534). ). CV (0.1 M TRIS pH 8, 
K3[Fe(CN)6] Ered= -810 mV . 1H NMR (500 MHz, D2O) δ/ppm = 0.40 (s, 3H), 1.28 (d, J = 
6.3 Hz, 3H), 1.36 (s, 3H), 1.39 (s, 3H), 1.42 (s, 3H), 1.79 (s, 3H), 1.93 (s, 3H), 2.27 (s, 3H), 
2.29 (s, 3H), 2.58 (s, 3H), 2.61 (s, 3H), overlapped by 1.09-2.80 (m, 38H), 3.00 (dd, J = 14.4, 
9.2 Hz, 1H), 3.39 (d, J = 9.1 Hz, 1H), 3.65 (d, J = 14.3 Hz, 1H), 3.79 (dd, J = 12.9, 3.7 Hz, 
1H), 3.94 (d, J = 10.6 Hz, 1H), 4.06 – 4.11 (m, 2H), 4.24 (dd, J = 9.3, 5.9 Hz, 3H), 4.30 – 
4.35 (m, 2H), 6.38 (d, J = 3.0 Hz, 1H), 6.51 (s, 1H), 7.11 (s, 1H), 7.32 (s, 1H). 
 
10-chloro-cyanocobalamin-c-lactone (5). Vitamin B12 (200 mg, 148 Pmol, 1 equiv) was 
dissolved in glacial acetic acid (3 mL) and NCS (20 mg, 150 μmol, 1.0 equiv) was added over 
a period of 3 h. The resulting dark purple solution was purified with solid phase extraction 
(SPE) and preparative HPLC. Solvents were removed under vacuum. 5 (14 mg, 10 μmol, 7%) 
was obtained as a purple powder. UV-vis (c = 1.80.10-5M; H2O) O/nm (log ε) = 281 (3.2), 289 
(3.2), 363 (4.6), 421 (3.4), 551 (3.6), 577 (3.6); HPLC tR = 17.45 min; ESI-MS (H2O:MeOH 
1:1) m/z = 694.7 [100%; M+2H]2+, 1388.2 [70%; M+H]+ (m/zcalc for C63H85CoN13O15PCl: 
1388.50); HR-ESI-MS (MeOH NaI): m/z = 694.75596 [M+2H]2+ (m/zcalc for 
C63H85CoN13O15PCl:  694.75568) CV (0.1 M TRIS buffer at pH 8, K3[Fe(CN)6] Ered= -784 
mV; 1H NMR (500 MHz, CD3OD, TMS) δ/ppm = 0.40 (s, 3H), 1.25 (d, 3H), 1.29 (s, 3H), 
1.79 (s, 3H), 2.00 (s, 3H), 2.29 (s, 3H), 2.31 (s, 3H), 2.62 (s, 3H), 2.63 (s, 3H), overlapped by 
1.79-2.87 (m, ~46H), 3.39 (d, J = 9.4, 1H), 3.67 (d, J = 14.0 Hz, 1H), 3.76-3.92 (m, 1H), 4.08 
(m, 1H), 4.20 (m, 1H), 4.54 (m, 1H), 4.62 (m, 1H), 6.32 (d, J = 2.9 Hz, 1H), 6.46 (s, 1H), 7.14 
(s, 1H), 7.34 (s, 1H). 
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c-(α,α-dibromo)-lactone-cyanocobalamin (6): The synthesis was performed according to 
recent literature procedures.S3  
 
c-(α,α-dichloro)-lactone-cyanocobalamin (7): To vitamin B12 (100 mg, 74 μmol, 1 equiv) 
dissolved in glacial AcOH (3 ml), NCS (99 mg, 744 μmol, 10 equiv) was added in one 
portion. The dark red solution was stirred at rt for 1 h. The resulting dark violet solution was 
desalted with solid phase extraction (SPE) and the solvents were removed under vacuum. 
Purification by preparative HPLC and lyophilization afforded 3 (58 mg, 41 μmol, 55%) as a 
violet powder. UV-vis (c = 4.21.10-5M; H2O) O/nm (log ε) = 279 (4.0), 288sh (3.9), 310 (3.8), 
363 (4.2), 412 (3.3), 531 (3.7), 554 (3.7); HPLC (Method 1) tR = 19.0 min; ESI-MS 
(H2O:MeOH 1:1) m/z = 712.7 [100%; M+2H]2+, 1424.4 [85%; M+H]+ (m/zcalc for 
C63H84CoN13O15PCl2: 1424.4); HR-ESI-MS (MeOH, NaI): m/z = 711.73666 (m/zcalc for 
C63H85CoN13O15PCl2: 711.73619) CV (0.1 M TRIS  pH 8, K3[Fe(CN)6] Ered= -715 mV; 1H-
NMR (500 MHz, 300 K, D2O) δ/ppm = 0.54 (s, 3H), 1.16 (s, 3H), 1.26 (d, JH,H = 6.5 Hz, 3H), 
1.41 (s, 3H), 1.47 (s, 3H), 1.54 (s, 3H), 2.10 (s, 3H), 2.29 (s, 3H), 2.33 (s, 3H), 2.63 (s, 3H), 
2.74 (s, 3H), overlapped by 1.21-2.80 (m, ~36H), 2.96-3.00 (m, 1H), 3.39 (t, JH,H = 5.5 Hz, 
1H), 3.61 (d, JH,H = 14.5 Hz, 1H), 3.76 (dd, JH,H = 4.0 Hz, 13.0 Hz, 1H), 3.94 (dd, JH,H = 2.5 
Hz, 13.0 Hz, 1H), 4.07-4.09 (m, 1H), 4.18 (d, JH,H = 8.5 Hz, 1H), 4.23 (d, JH,H = 9.5 Hz, 1H), 
4.29-4.35 (m, 2H), 6.12 (s, 1H), 6.39 (d, JH,H = 4.5 Hz, 1H), 7.10 (s, 1H), 7.34 (s, 1H). 13C-
NMR (126 MHz, 300 K, CD3OD) δ/ppm= 182.2,181.0,180.0, 177.6, 177.4, 175.5, 175.3, 
175.3, 174.5, 167.5, 166.6, 166.3, 158.6, 143.4, 132.2, 134.3, 131.6, 127.1, 116.8, 113.1, 
110.8, 107.7, 93.3., 92.2, 88.2, 86.7, 84.9, 76.6, 75.2, 73.6, 70.5, 65.2, 62.3, 60.6, 57.6, 55.0, 
50.3, 46.7, 43.0, 40.1, 40.1, 36.1, 35.3, 32.2,  31.9, 31.8, 31.6, 30.1, 29.7, 29.5, 27.5, 25.00, 
24.00, 21.1, 20.6, 20.3, 20.1, 19.2, 17.6, 17.5, 16.7, 16.3.  
Cyanocobalamin-P-CN-[Re(CO)2Br2(CH3OH)] (8). The synthesis was performed by 
modifications of a reported procedure.S4 Vitamin B12 (100 mg, 74 μmol, 1 equiv) and 1 (114 
mg, 164 μmol, 2.2 equiv) were stirred in MeOH (60 mL) at 50 ºC for 90 minutes. The solvent 
was subsequently removed and the resulting red powder was washed several times with 
dichloromethane (20 mL) and acetone (20 mL). 8 (105.9 mg, 59 μmol, 80%) was obtained as 
a red microcrystalline powder. UV-vis (c = 1.81.10-4 M; H2O) O/nm (log ε) = 276 (3.9), 323 
(3.9), 361 (4.3), 407 (3.3), 518 (3.7), 547 (3.7); ESI-MS (H2O:MeOH 1:1) m/z = 865.6 
[100%; M+2H]2+, 1757.7 [70%; M+H]+ (m/zcalc for C63H88CoN14O14PReC2O2Br2: 1755.35). 
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IR (solid state, KBr, cm-1) v C≡N = 2184, v C≡O =1989, 1839. ICP/OES measurements of Re 
content by relative weight: calcd 10.41; found 9.88 ± 0.05. 
 
Cyanocobalamin-c-lactone-P-CN-[Re(CO)2Br2(CH3OH)] (9). 2 (15.9 mg, 12 μmol, 1 
equiv) and 1 (20 mg, 29 μmol, 2.4 equiv) were dissolved in methanol (10 mL) and stirred at 
50ºC for 90 minutes. The solvent was subsequently removed and the resulting red powder was 
washed several times with dichloromethane (20 mL) and acetone (20 mL).  9 was obtained as 
a red microcrystalline powder (16.5 mg, 9 μmol, 75%). UV-vis (c = 1.81.10-4 M; H2O) O/nm 
(log ε) = 276 (4.0), 323 (3.7), 361 (4.3), 407 (3.4), 518 (3.6), 547 (3.6); HR-ESI-MS 
(H2O:MeOH 1:1) m/z = 894.3 [100%; M+2H]2+, 1757.3235 [100%; M+H]+ (m/zcalc for 
C63H86CoN13O15PReC2O2Br2:  1757.3236). IR (solid state, KBr, cm-1) v C≡N 2190, v C≡O 1989, 
1841, 1789 (v C=O lactone). ICP/OES measurements of Re content by relative weight: calcd 
10.41; found 9.89 ± 0.32. 
 
10-bromo-cyanocobalamin-P-CN-[Re(CO)2Br2(CH3OH)] (10). 3 (8 mg, 5.5 μmol, 1 equiv) 
and 1 (10 mg, 14 μmol, 2.5 equiv) were dissolved in methanol (7 ml) and stirred for 30 
minutes at 50 ºC. The solvent was subsequently removed and the resulting red powder was 
washed several times with dichloromethane (20 mL) and acetone (20 mL). 10 was obtained as 
a dark red microcrystalline powder (7.5 mg, 4 μmol, 66%). UV-vis (c = 1.89.10-4 M; H2O) 
O/nm (log ε) = 279 (3.9), 366 (4.3), 411 (3.3), 550 (3.6), 574 (3.6); HR-ESI-MS (H2O:MeOH 
1:1) m/z = 1836.2687 [100%; M+H]+ (m/zcalc for C63H88CoN14O14PReC2O2Br3: 1836.2647). 
IR (solid state, KBr, cm-1) Q C≡N = 2176, Q C≡O = 1992, 1845. ICP/OES measurements of Re 
content by relative weight: calcd 9.96; found 9.33 ± 0.12. 
 
10-chloro-cyanocobalamin-P-CN-[Re(CO)2Br2(CH3OH)] (11). 4 (20 mg, 14 μmol, 1equiv) 
and 1 (34 mg, 48 μmol, 3.5 equiv) were dissolved in methanol (12 mL) and stirred for 30 
minutes at 50 ºC. The solvent was subsequently removed and the resulting red powder was 
washed several times with dichloromethane (20 mL) and acetone (20 mL). 11 was obtained as 
a purple microcrystalline powder (10.5 mg, 6 μmol, yield 85%). UV-vis (c = 1.84.10-4 M; 
H2O) O/nm (log ε) = 279 (3.9), 287 (3.9), 363 (4.2), 415 (2.3), 545 (3.6), 570 (3.6); HR-ESI-
MS (H2O:MeOH 1:1) m/z = 1792.3110 [100%; M+H]+ (m/zcalc for 
C63H88CoN14O14PClReC2O2Br2: 1792.3156). IR (solid state, KBr, cm-1) v C≡N = 2178, v C≡O 
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=1973, 1841. ICP/OES measurements of Re content by relative weight: calcd 10.20; found 
9.79 ± 0.23. 
 
10-chloro-cyanocobalamin-c-lactone-P-CN-[Re(CO)2Br2(CH3OH)] (12). 5 (6.5 mg, 5 
μmol, 1 equiv) and 1 (8 mg, 11 μmol, 2.2 equiv) were dissolved in methanol (6 mL) and the 
mixture was stirred for 20 minutes at 50 ºC. The solvent was subsequently removed and the 
resulting red powder was washed several times with dichloromethane (15 mL) and acetone 
(15 mL).  12 was obtained as a dark purple microcrystalline powder (7.9 mg, 4 μmol, 80%). 
UV-vis (c = 1.84.10-4 M; H2O) O/nm (log ε) = 277 (3.2), 285 (3.2), 362 (4.2), 417 (3.4), 545 
(3.6), 570 (3.6); ESI-MS (H2O:MeOH 1:1) m/z = 895.3 [100%; M+2H]2+, 1790.6 [70%; 
M+H]+ (m/zcalc for C63H86ClCoN13O15PReC2O2Br2: 1790.29). IR (solid state, KBr, cm-1) v C≡N 
= 2124, v C≡O = 1988, 1840, 1783. ICP/OES measurements of Re content by relative weight: 
calcd 10.20; found 9.75 ± 0.36. 
 
c-(α,α-dibromo)-lactone-cyanocobalamin-P-CN-[Re(CO)2Br2(CH3OH)] (13). 6 (10.5 mg, 
7 μmol, 1equiv) and 1 (12 mg, 17 μmol, 2.4 equiv) were dissolved in methanol (5 ml) and 
stirred for 30 minutes at 50 ºC. The solvent was subsequently removed and the resulting red 
powder was washed several times with dichloromethane (20 mL) and acetone (20 mL).13 was 
obtained as a dark purple microcrystalline powder (10 mg, 5.2 μmol, 75%). UV-vis (c = 
1.63.10-4 M; H2O) O/nm (log ε) = 278 (4.1), 311 (3.9), 363 (4.2), 413 (3.7), 529 (3.6), 558 
(3.6); HR-ESI-MS (H2O:MeOH 1:1) m/z = 1915.1439 [100%; M+H]+ (m/zcalc for 
C63H84Br2CoN13O15PReC2O2Br2: 1915.1426). IR (solid state, KBr, cm-1) v C≡N = 2181, v C≡O 
= 1987, 1841, 1794. ICP/OES measurements of Re content by relative weight: calcd 9.56; 
found 9.14 ± 0.05. 
 
c-(α,α-dichloro)-lactone-cyanocobalamin-P-CN-[Re(CO)2Br2(CH3OH)] (14). 7 (10 mg, 7 
μmol, 1equiv) and 1 (12 mg, 17 μmol, 2.4 equiv) were dissolved in methanol (7 ml) and 
stirred for 25 minutes at 50 ºC. The solvent was subsequently removed and the resulting red 
powder was washed several times with dichloromethane (20 mL) and acetone (20 mL).14 was 
obtained as a dark purple microcrystalline powder (10 mg, 5.2 μmol, 77%). UV-vis (c = 
1.81.10-4 M; H2O) O/nm (log ε) = 278 (3.6), 288 (3.5), 310 (3.4), 362 (4.2), 413 (3.1), 527 
(3.6), 553 (3.6); HR-ESI-MS (H2O:MeOH 1:1) m/z = 1825.2319 [100%; M+H]+ (m/zcalc for 
C63H84Cl2CoN13O15PReC2O2Br2: 1825.2445). IR (solid state, KBr, cm-1) v C≡N = 2185, v C≡O = 
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1988, 1838, 1808. ICP/OES measurements of Re content by relative weight: calcd 10.02; 
found 9.67 ± 0.10. 
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Figure S1. Top: 1H-NMR spectrum of cyanocobalamin-c-lactone (2) recorded in D2O [500 
MHz]. Bottom: measured (top row) and calculated (bottom row) ESI-MS spectra of 2. 
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Figure S2. Top: 1H-NMR spectrum of 10-bromo-cyanocobalamin (3) recorded in D2O [500 
MHz]. Region of missing H10 signal is assigned. Bottom: measured (top row) and calculated 
(bottom row) ESI-MS spectra of 3. 
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Figure S3. Top: 1H-NMR spectrum of 10-chloro-cyanocobalamin (4) recorded in D2O [500 
MHz]. Region of missing H10 signal is assigned. Bottom: measured (top row) and calculated 
(bottom row) ESI-MS spectra of 4. 
S15 
 
 
 
 
 
Figure S4. Top: 1H-NMR spectrum of 10-chloro-lactone cyanocobalamin (5) recorded in 
CD3OD/TMS [500 MHz]. Region of missing H10 signal is assigned. Bottom: measured (top 
row) and calculated (bottom row) ESI-MS spectra of 5. 
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Figure S5. Top: 1H-NMR spectrum of c-(α,α-dibromo)-lactone-cyanocobalamin (6) recorded 
in D2O//TMS [500 MHz]. H10 signal is assigned. Bottom: measured (top row) and calculated 
(bottom row) ESI-MS spectra of 6. 
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Figure S6. Top: 1H-NMR spectrum of c-(α,α-dichloro)-lactone-cyanocobalamin (7) recorded 
in D2O//TMS [500 MHz]. H10 signal is assigned. Bottom: 13C-NMR spectrum of 7 recorded 
in CD3OD [126 MHz]. 
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Figure S7. Measured (top row) and calculated (bottom row) ESI-MS spectra of 7. 
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Figure S8. Cyclovoltammograms of (from top to bottom) 2, 4 and 7.Red/solid arrow: 
reduction potential of CoIII > CoI.  
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Figure S9. IR spectra of 9, 10, 11, 12, 13 and 14. 
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Figure S10. UV-visible spectra of an unbuffered aqueous solution of B12 (black line) and 8 
(red line). 
 
 
 
Figure S11. UV-visible spectra of an unbuffered aqueous solution of 2 (black line) and 9 (red 
line). 
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Figure S12. UV-visible spectra of an unbuffered aqueous solution of 3 (black line) and 10 
(red line). 
 
 
 
Figure S13. UV-visible spectra of an unbuffered aqueous solution of 6 (black line) and 13 
(red line). 
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Figure S14. HR-ESI-MS (H2O:MeOH 1:1) spectrum of 9. 
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Figure S15. HR-ESI-MS (H2O:MeOH 1:1) spectrum of 10. 
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Figure S16. HR-ESI-MS (H2O:MeOH 1:1) spectrum of 11. 
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Figure S17. HR-ESI-MS (H2O:MeOH 1:1) spectrum of 13. 
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Figure S18. HR-ESI-MS (H2O:MeOH 1:1) spectrum of 14. 
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Figure S19. Changes in the UV-visible spectrum of an unbuffered aqueous solution of 
selected B12-ReCORM species. Spectra were recorded at fixed time intervals at 25 qC. 
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Figure S20. Normalized exponential hypochromic shift of 410 nm band in the UV-Vis 
spectrum of compounds 8-14 in H2O. 
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Figure S21. Normalized exponential hypochromic shift of 410 nm band in the UV-Vis 
spectrum of compounds 8-14 in DMSO. 
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Table S1. Half-life (t½) of stability of species 8-14 in DMSO. 
Compound t½ hypochromic shift of 410 nm band in DMSO a 
8 2.3 r 0.3 
9 1.6 r 0.6 
10 0.99 r 0.2 
11 > 3 
12 n. d. 
13 1.9 r 0.4 
14 > 3 
a Assuming a first order exponential decay (hours). 
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Figure S22. Spectrum changes (5 min intervals) of a solution of deoxy-myoglobin (Mb, 20 
PM, phosphate buffer, pH = 7.4) solution after addition of 1 equivalent of species 8-14.  
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Figure S23. The formation of MbCO in sixth (A-C) and fifteenth (D-F) minutes of B12-
ReCORM complexes 8-14 incubation with Mb (mean and standard deviation of N = 4-5) 
normalized to MbCO formation for B12-ReCORM. 
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